VentureMed Group, a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced data presented at the VEITHsymposium, (15–19 November, New York, USA). Overall, the data presented demonstrated that Flex vessel prep used prior to balloon angioplasty improves 12-month […]
The post “Impressive” 12-month Flex vessel prep data presented at VEITHsymposium appeared first on Vascular News.
Boston Scientific has announced that it will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec Scientific, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures. The proposed price is HK$20 per share, which represents a total upfront cash […]
The post Boston Scientific announces investment to acquire majority stake of Acotec Scientific appeared first on Vascular News.
Endologix recently announced that it has received US Food and Drug Administration (FDA) approval for a premarket approval (PMA) supplement relating to the AFX2 system. According to a company press release, Endologix received approval to include an updated warning and the most contemporary clinical information in the labelling for the AFX2 system. Clinical data added […]
The post Endologix receives US FDA approval of PMA supplement for AFX2 system appeared first on Vascular News.
Data have been presented for the first time at the Paris Vascular Insights (PVI) conference (23–25 November, Paris, France) from the ABISS trial, which compared drug-coated balloon (DCB) with plain-balloon angioplasty for arteriovenous fistula (AVF) stenosis. ABISS was a physician-designed prospective, randomised, double-blind trial that included 12 centres in France. The study enrolled 150 adult […]
The post ABISS trial comparison finds DCB superior to plain-balloon angioplasty in per-protocol analysis appeared first on Vascular News.
A prospective study has demonstrated the potential feasibility, applicability and accuracy held by artificial intelligence (AI) in the detection of carotid artery disease on greyscale static duplex ultrasound imaging. This is the conclusion reached by Ali Kordzadeh (Faculty of Science and Engineering, Anglia Ruskin University, Chelmsford, UK) and colleagues in the journal Vascular. “This network […]
The post AI demonstrates potential to detect carotid artery disease on duplex ultrasound appeared first on Vascular News.
The President’s Symposium at the Vascular Society of Great Britain and Ireland (VSGBI) annual scientific meeting (23–25 November, Brighton, UK) featured Rob Sayers’ (University of Leicester, UK) presentation titled ‘CLTI CQUIN has raised the profile of PAD and will lead to fewer amputations’. Sayers’ take-home message for delegates was that the National Health Service (NHS)’s […]
The post VSGBI President’s Symposium spotlights data-driven financial incentives for PAD revascularisation appeared first on Vascular News.
Viz.ai recently announced new data from a large aortic dissection artificial intelligence (AI) real-world study that supports the use of its AI technology for the detection of suspected aortic dissection. Data from the new study, which were presented this week at VEITHsymposium 2022 (15–19 November, New York, USA), validate the company’s industry-leading dissection detection algorithm, part […]
The post Viz.ai announces positive new data from large aortic dissection AI real-world study at VEITHsymposium 2022 appeared first on Vascular News.
The Sundance (Surmodics) sirolimus drug-coated balloon (DCB) has an “excellent” safety profile in a “challenging, real-world, predominantly CLTI [chronic limb-threatening ischaemia] population,” and has a primary patency rate of 80% at 12 months in a per-protocol analysis population. Ramon Varcoe (Prince of Wales Hospital, Sydney, Australia) presented these findings from the SWING first-in-human study at […]
The post SWING trial 12-month data: Novel sirolimus DCB shows “great promise” in “challenging” CLTI population appeared first on Vascular News.
Genesis MedTech Group announced that the US Food and Drug Administration (FDA) has approved the Chocolate Touch drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) catheter, developed by TriReme Medical, for the treatment of patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and the popliteal artery. The Chocolate Touch DCB was shown […]
The post Chocolate Touch drug-coated angioplasty balloon for treatment of PAD receives FDA approval appeared first on Vascular News.
Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The late-breaking data were presented at the American Heart Association (AHA) Scientific Sessions 2022 (5–7 November, Chicago, USA). With this news, Medtronic has submitted the final module of the Symplicity Spyral premarket approval (PMA) package to the US Food […]
The post SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials appeared first on Vascular News.